Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Surveillance cameras and security systems are often used to protect against criminal activity. Their effectiveness, however, depends on their ability to identify suspicious activity.
Just as some criminals can avoid detection by obscuring themselves from surveillance cameras, cancer cells in the body have features that enable them to evade the body's immune system.
To this end, researchers are developing new strategies—collectively known as immunotherapy—to boost the immune system's ability to detect and eliminate tumours.
Among the many types of immunotherapy is a class of drugs known as checkpoint inhibitors, which 'release the brakes' on the immune system and unleash powerful immune cells that migrate to and destroy tumours.
The checkpoint inhibitor, ipilimumab, is an effective drug for several types of cancer, but its usefulness in treating women with cervical cancer—over 90 per cent of whom have an associated infection with human papillomavirus (HPV)—is not known.
Dr. Amit Oza, clinical researcher at the Princess Margaret and Director of the Bras Family Drug Development Program, initiated a clinical trial to address this gap in knowledge. A part of the Princess Margaret Phase II Consortium, the trial followed 42 women with HPV-related cervical cancer who were treated with ipilimumab. The drug was generally considered safe, although some unwanted effects were seen in certain patients.
The research team found few immune cells were present in patients' tumour tissues, suggesting that immune cells were not migrating to the tumour. Furthermore, the treatment did not stop the progression of cancer in the majority of patients. The team also found immune cells circulating in the blood were primed for action, despite the lack of anti-tumour activity.
"Our study is the first to evaluate the effectiveness of ipilimumab in HPV-associated cervical cancer," says Dr. Oza. "While the drug did not demonstrate significant anti-tumour activity on its own, it is clearly activating immune cells in the blood."
"As such, its effectiveness combined with other drugs—for example those that target cancer's ability to evade the immune system—warrants further investigation."
This work was supported by the National Institutes of Health and The Princess Margaret Cancer Foundation.